Literature DB >> 33679798

Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT.

Nicola Tumino1, Anna Laura Di Pace1, Francesca Besi1, Linda Quatrini1, Paola Vacca1, Lorenzo Moretta1.   

Abstract

Myeloid derived suppressor cells (MDSC) are heterogeneous populations that through the release of soluble factors and/or by cell-to-cell interactions suppress both innate and adaptive immune effector cells. In pathological conditions, characterized by the presence of inflammation, a partial block in the differentiation potential of myeloid precursors causes an accumulation of these immunosuppressive cell subsets both in peripheral blood and in tissues. On the contrary, NK cells represent a major player of innate immunity able to counteract tumor growth. The anti-tumor activity of NK cells is primarily related to their cytolytic potential and to the secretion of soluble factors or cytokines that may act on tumors either directly or indirectly upon the recruitment of other cell types. NK cells have been shown to play a fundamental role in haploidentical hemopoietic stem cell transplantation (HSCT), for the therapy of high-risk leukemias. A deeper analysis of MDSC functional effects demonstrated that these cells are capable, through several mechanisms, to reduce the potent GvL activity exerted by NK cells. It is conceivable that, in this transplantation setting, the MDSC-removal or -inactivation may represent a promising strategy to restore the anti-leukemia effect mediated by NK cells. Thus, a better knowledge of the cellular interactions occurring in the tumor microenvironment could promote the development of novel therapeutic strategies for the treatment of solid and hematological malignances.
Copyright © 2021 Tumino, Di Pace, Besi, Quatrini, Vacca and Moretta.

Entities:  

Keywords:  hematological malignancies; hematopoietic stem cell transplantation; myeloid-derived suppressor cells; natural killer cells; tumor microenvironment

Year:  2021        PMID: 33679798      PMCID: PMC7928402          DOI: 10.3389/fimmu.2021.638841

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  13 in total

Review 1.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 2.  MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.

Authors:  Chiara Cioccarelli; Barbara Molon
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

Review 3.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

Review 4.  NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment.

Authors:  Eleonora Russo; Mattia Laffranchi; Luana Tomaipitinca; Annalisa Del Prete; Angela Santoni; Silvano Sozzani; Giovanni Bernardini
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

5.  Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.

Authors:  Paola Vacca; Ignazio Caruana; Nicola Tumino; Gerrit Weber; Francesca Besi; Francesca Del Bufalo; Valentina Bertaina; Paola Paci; Linda Quatrini; Laura Antonucci; Matilde Sinibaldi; Concetta Quintarelli; Enrico Maggi; Biagio De Angelis; Franco Locatelli; Lorenzo Moretta
Journal:  J Hematol Oncol       Date:  2021-11-12       Impact factor: 17.388

Review 6.  Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.

Authors:  Adeleye O Adeshakin; Funmilayo O Adeshakin; Dehong Yan; Xiaochun Wan
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

Review 7.  Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options.

Authors:  Zuzanna Sas; Ewa Cendrowicz; Isabel Weinhäuser; Tomasz P Rygiel
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

8.  Natural killer cells act as an extrinsic barrier for in vivo reprogramming.

Authors:  Elena Melendez; Dafni Chondronasiou; Lluc Mosteiro; Jaime Martínez de Villarreal; Marcos Fernández-Alfara; Cian J Lynch; Dirk Grimm; Francisco X Real; José Alcamí; Núria Climent; Federico Pietrocola; Manuel Serrano
Journal:  Development       Date:  2022-04-22       Impact factor: 6.862

Review 9.  PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.

Authors:  Enrico Munari; Francesca R Mariotti; Linda Quatrini; Pietro Bertoglio; Nicola Tumino; Paola Vacca; Albino Eccher; Francesco Ciompi; Matteo Brunelli; Guido Martignoni; Giuseppe Bogina; Lorenzo Moretta
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

Review 10.  Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.

Authors:  Nicola Tumino; Francesca Besi; Stefania Martini; Anna Laura Di Pace; Enrico Munari; Linda Quatrini; Andrea Pelosi; Piera Filomena Fiore; Giulia Fiscon; Paola Paci; Francesca Scordamaglia; Maria Grazia Covesnon; Giuseppe Bogina; Maria Cristina Mingari; Lorenzo Moretta; Paola Vacca
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.